Choose a language and wait for the translated text.
Shots:
The US FDA has granted De Novo authorization to Roche’s cobas pro i 601 platform with the Ionify Gabapentin assay, part of its cobas Mass Spec solution, bringing automated mass spectrometry into routine clinical laboratories for therapeutic drug monitoring
The Ionify Gabapentin assay adds a TDM application to Roche’s US mass spectrometry menu, which already includes 25-Hydroxy Vitamin D total and steroid hormone assays such as estradiol and 17-Hydroxyprogesterone
An FDA-authorized Predetermined Change Control Plan (PCCP) will allow Roche to add up to 22 additional Ionify assays on the cobas pro i 601 platform as PCCP requirements are met; these additional assays are not yet available
Ref: Roche | Image: Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post The US FDA Grants De Novo Authorization to Roche’s cobas pro i 601 Platform with the Ionify Gabapentin Assay appeared first on PharmaShots.
The US FDA Grants De Novo Authorization to Roche’s cobas pro i 601 Platform with the Ionify Gabapentin Assay | PharmaVoice